In this article, we showed that FGFR1 is amplified in lung cancer, breast cancer and, rarely, in pancreatic cancer and squamous cell cancer, whereas FGFR2 amplification mainly occurs in gastric cancer and breast cancer. Here, FGFR2 is linked to breast carcinoma.